glp-1 news today cardiovascular outcomes 2025 november Frontiers GLP-1 Agonists Weight Loss Drugs

B.MattarelliP.et al

Ese peso extra puede aumentar el riesgo de recurrencia o nuevos cnceres

Clinical trial data for semaglutide points to average losses of around 15% of body weight over 68 weeks when combined with diet and lifestyle changes

Continuous vs

While amyloid-PET is a frequently used response biomarker that has already been incorporated into regulatory approval processes for AD evaluation and treatments, the identification of additional response biomarkers is an active area of investigation

However, the evidence is still evolving related to how these medications may impact complications related to obesity such as heart disease and diabetes. The Pharmaceutical Strategies Group (PSG), a pharmaceutical management consulting company, surveyed 180 benefits executives representing health plans, employers and unions and found that these drugs are a major concern